Safety and Efficacy Study of DCVax-Direct in Solid Tumors

• ClinicalTrials.gov Identifier: NCT01882946
• Recruitment Status: Unknown
• First Posted: June 21, 2013
• Last Update Posted: October 7, 2015
• Sponsor: Northwest Biotherapeutics
• Information provided by (Responsible Party): Northwest Biotherapeutics

Study Description

Brief Summary:

The study comprises a Phase I component during which the optimal dose of DCVax-Direct for the treatment of solid tissue tumors will be identified, followed by a Phase II component to determine if the injection of DCVax-Direct into selected solid tissue tumors has the ability to reduce tumor growth.

Condition or disease	Intervention/treatment	Phase
Locally Advanced Tumor; Metastatic Solid Tissue Tumors; Liver Cancer; Colorectal Cancer; Pancreatic Cancer; Melanoma	Biological: DCVax-Direct	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 60 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS
• Study Start Date: June 2013
• Estimated Primary Completion Date: December 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: DCVax-Direct; DCVax-Direct: autologous, activated dendritic cells for intratumoral injection	Biological: DCVax-Direct; Autologous, activated dendritic cells for intratumoral injection

Outcome Measures

Primary Outcome Measures :

1. Number of patients with adverse events [ Time Frame: 6 months ]

Secondary Outcome Measures :

1. Number of patients with tumor response [ Time Frame: 18 months ]

Other Outcome Measures:

1. Number of patients surviving [ Time Frame: 24 months ]
2. Number of patients surviving without tumor progression [ Time Frame: 24 months ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria (summary):

• Age between 18 and 75 years (inclusive) at screening.
• Karnofsky performance status (KPS) of 70 or higher or Eastern Cooperative Oncology Group (ECOG) 0-1 at screening.
• Subjects with a histological or cytopathological confirmed diagnosis of a locally advanced or metastatic solid tumor malignancy for which primary treatment is no longer effective or does not offer curative or life-prolonging potential per clinician judgment, with the understanding that DCVax-Direct is not intended as a treatment of last resort.
• Not eligible for complete resection due to either tumor location, physician's assessment or subject's choice.
• Must have completed at least one recent treatment regimen in the metastatic or advanced setting in the disease currently under treatment to reduce tumor burden.
• Any steroid therapy >2 mg dexamethasone or equivalent dose should be stopped or have been tapered down 2 weeks prior to the leukapheresis.
• At least one measurable tumor mass, i.e. a lesion that can accurately be measured by CT/MRI in at least one dimension with longest diameter ≥ 1 cm, that is accessible for injection either with or without imaging (CT/ultrasound) guidance.
• Adequate hematological, hepatic, and renal function,
• Adequate blood coagulation parameters
• Life expectation of >3 months.

Exclusion Criteria (Summary):

• Positive HIV-1, HIV-2, or Human T-lymphotropic virus (HTLV-I/II) tests.
• History of current or prior (within the last two years) active clinically significant malignancy other than the tumor type for which DCVax-Direct treatment is considered, and except for primary tumor in the case of metastases and adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
• Heavily pretreated (HP) subjects are not eligible for this study, unless treatments have occurred more than 1 year in the past.
• Presence of brain metastases, unless treated surgically and/or irradiated and clinically stable off steroids or on low dose (< 2 mg per day) steroids for ≥ 14 days, or presence of leptomeningeal disease.
• History of immunodeficiency or unresolved autoimmune disease.
• Requirement for ongoing immunosuppressants.
• Prior active immunotherapy for cancer within the past 2 years.
• Ongoing medical need for continuous anti-coagulation or anti-platelet medication.
• Known genetic cancer-susceptibility syndromes.
• Acute or active uncontrolled infection
• Ongoing fever ≥ 101.5 degrees F/38.6 degrees C at screening.
• Unstable or severe intercurrent medical conditions such as unstable angina, uncontrolled arrhythmias, Crohn's Disease, ulcerative colitis etc.
• Females of child-bearing potential who are pregnant or lactating or who are not using adequate contraception (surgical, hormonal or double barrier, i.e. condom and diaphragm).
• Allergy or anaphylaxis to any of the reagents used in this study.
• Inability to obtain informed consent because of psychiatric or complicating medical problems.
• Inability or unwillingness to return for required visits and follow-up exams.

Contacts and Locations

Locations

United States, Florida

Orlando Health

Orlando, Florida, United States, 32806

United States, Texas

MD Anderson Cancer Center

Houston, Texas, United States, 77030

Sponsors and Collaborators

Northwest Biotherapeutics

Investigators

• Study Director: Marnix Bosch, MBA, PhD; Northwest Biotherapeutics

More Information

• Responsible Party: Northwest Biotherapeutics
• ClinicalTrials.gov Identifier: NCT01882946
• Other Study ID Numbers: NWBio 050012
• First Posted: June 21, 2013
• Last Update Posted: October 7, 2015
• Last Verified: October 2015

Additional relevant MeSH terms:

Neoplasms